Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 7/16/19 (What's New)

Summary

  • No randomized, controlled trials to guide clinicians in the face of a less than fully suppressive regimen, but stopping all therapy puts patients at risk for disease progression[Deeks 2001; SMART 2006; Lawrence 2003]
  • Some drugs have demonstrated little benefit when continued in the face of drug resistance, such as NNRTIs and enfuvirtide[Deeks 2005; Deeks 2007]
  • Continuing some failing regimens may be of little or no benefit and may select for additional resistance mutations, limiting responses to second-generation agents

Action required